Altogether, these data confirm that agents that can block CEMIP activity are capable of promoting OPC maturation, and support the notion that CEMIP inhibitors have the potential to be used to promote OPC maturation and remyelination in demyelinating diseases. The gene discussed is CEMIP; the disease is demyelinating disease.